The characteristic features of the topical therapy of atopic dermatitis: a modern interpretation

2015 ◽  
Vol 14 (6) ◽  
pp. 103
Author(s):  
O. V. Zhukova ◽  
L. S. Kruglova ◽  
R. I. Ptashinskiy ◽  
S. A. Masyukova
Keyword(s):  
Atopic Dermatitis ◽  
Topical Therapy ◽  
Characteristic Features

scholarly journals Transcutaneous penetration of a single-chain variable fragment (scFv) compared to a full-size antibody: potential tool for atopic dermatitis (AD) treatment

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Audrey Baylet ◽  
Raoul Vyumvuhore ◽  
Marine Laclaverie ◽  
Laëtitia Marchand ◽  
Carine Mainzer ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Ex Vivo ◽  
Topical Therapy ◽  
Human Keratinocytes ◽  
Raman Microspectroscopy ◽  
Interleukin 4 ◽  
Single Chain Variable Fragment ◽  
Single Chain ◽  
Administration Routes

AbstractCurrently, several biologics are used for the treatment of cutaneous pathologies such as atopic dermatitis (AD), psoriasis or skin cancers. The main administration routes are subcutaneous and intravenous injections. However, little is known about antibody penetration through the skin. The aim was to study the transcutaneous penetration of a reduced-size antibody as a single-chain variable fragment (scFv) compared to a whole antibody (Ab) and to determine its capacity to neutralize an inflammatory cytokine involved in AD such as human interleukin-4 (hIL-4). Transcutaneous penetration was evaluated by ex vivo studies on tape-stripped pig ear skin. ScFv and Ab visualization through the skin was measured by Raman microspectroscopy. In addition, hIL-4 neutralization was studied in vitro using HEK-Blue™ IL-4/IL-13 cells and normal human keratinocytes (NHKs). After 24 h of application, analysis by Raman microspectroscopy showed that scFv penetrated into the upper dermis while Ab remained on the stratum corneum. In addition, the anti-hIL4 scFv showed very efficient and dose-dependent hIL-4 neutralization. Thus, scFv penetrates through to the upper papillary dermis while Ab mostly remains on the surface, the anti-hIL4 scFv also neutralizes its target effectively suggesting its potential use as topical therapy for AD.

scholarly journals Overcoming drug delivery barriers and challenges in topical therapy of atopic dermatitis: A nanotechnological perspective

2022 ◽  
Vol 147 ◽  
pp. 112633
Author(s):  
Chetna Hemrajani ◽  
Poonam Negi ◽  
Arun Parashar ◽  
Gaurav Gupta ◽  
Niraj Kumar Jha ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Atopic Dermatitis ◽  
Topical Therapy ◽  
Barriers And Challenges

scholarly journals Transcutaneous penetration of a single-chain variable fragment (scFv) compared to a full-size antibody: potential tool for Atopic Dermatitis (AD) treatment

2021 ◽  
Author(s):  
Audrey Baylet ◽  
Raoul Vyumvuhore ◽  
Marine Laclaverie ◽  
Laëtitia Marchand ◽  
Carine Mainzer ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Ex Vivo ◽  
Topical Therapy ◽  
Human Keratinocytes ◽  
Raman Microspectroscopy ◽  
Poly I:C ◽  
Interleukin 4 ◽  
Single Chain Variable Fragment ◽  
Single Chain ◽  
Polycytidylic Acid

SummaryBackgroundCurrently, several biologics are used for the treatment of cutaneous pathologies such as atopic dermatitis (AD), psoriasis (PSO) or skin cancers. The main administration routes are subcutaneous and intravenous injections. However, little is known about antibody penetration through the skin.ObjectivesThe aim was to study the transcutaneous penetration of a reduced-size antibody as a single-chain variable fragment (scFv) compared to a whole antibody (Ab) and to determine its capacity to neutralize an inflammatory cytokine involved in AD such as human interleukin-4 (hIL-4).MethodsTranscutaneous penetration was evaluated by ex vivo studies on tape-stripped pig ear skin. Antibody visualization through the skin was measured by Raman microspectroscopy. In addition, hIL-4 neutralization was studied using two 2D models. First, embryonic alkaline phosphatase (SEAP) secretion by HEK-Blue™ IL-4/IL-13 cells, proportional to hIL-4 cells stimulation, was quantified by OD 620 nm measurement in presence or absence of an anti-hIL4 scFv or Ab. Then, normal human keratinocytes (NHKs) were stimulated with polyinosinic-polycytidylic acid (poly I:C) +/− hIL-4 and treated with anti-hIL4 scFv. Human Interleukin-8 (hIL-8) concentrations were determined in culture supernatants by ELISA.ResultsAfter 24h of application, analysis by Raman microspectroscopy showed that scFv penetrated into the upper dermis while Ab remained on the stratum corneum. In addition, the anti-hIL4 scFv showed better efficiency compared to Ab, with a neutralization percentage at 200 nM of 68% and 47%, respectively, in the HEK-Blue™ IL-4/IL-13 model. hIL-8 dosage in stimulated NHKs supernatants revealed that addition of scFv induced a dose-dependent hIL-4 neutralization.ConclusionsscFv penetrates through to the upper papillary dermis while Ab remains on the surface. The anti-hIL4 scFv neutralizes its target effectively in two 2D models suggesting its potential use as topical therapy for AD.

Supplementary therapy in canine atopic dermatitis

2019 ◽  
Vol 24 (8) ◽  
pp. 400-407
Author(s):  
Sue Paterson
Keyword(s):  
Fatty Acids ◽  
Atopic Dermatitis ◽  
Specific Immunotherapy ◽  
Essential Fatty Acids ◽  
Topical Therapy ◽  
Allergen Specific Immunotherapy ◽  
Canine Atopic Dermatitis ◽  
Adequate Control ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Therapy for canine atopic dermatitis can be described as foundation or supplementary. Foundation therapy, which refers to allergen-specific immunotherapy, ciclosporin, glucocorticoids, lokivetmab and oclacitinib, is needed in all but the mildest of cases of canine atopic dermatitis. Supplementary therapies include drugs such as antihistamines, essential fatty acids, topical therapy and other systemic anti-inflammatory drugs. While it is uncommon for any of these supplementary drugs to provide adequate control of many cases of canine atopic dermatitis, they can reduce the frequency of relapse and reduce the amount of foundation therapy that is required when used in combination with them.

Stepwise Approach to Topical Therapy for Atopic Dermatitis

2007 ◽  
Vol 47 (5) ◽  
pp. 423-434 ◽  
Author(s):  
Christine M. Palmer ◽  
Valerie B. Lyon
Keyword(s):  
Atopic Dermatitis ◽  
Topical Therapy ◽  
Stepwise Approach

scholarly journals Experience of combined topical therapy with methylprednisoloni aceponatis and «Bepanten Plus»® in treatment of adult patients with moderate and severe atopic dermatitis

2015 ◽  
Vol 12 (6) ◽  
pp. 80-83
Author(s):  
O K Shtyrbul ◽  
O A Erina ◽  
E S Fedenko
Keyword(s):  
Staphylococcus Aureus ◽  
Atopic Dermatitis ◽  
Combined Therapy ◽  
Topical Therapy ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Bacterial Isolation ◽  
Treatment Results ◽  
Lesional Skin ◽  
Days Of Therapy

Background. To estimate efficiency of combined therapy with methylprednisolone aceponatis and «Bepanten Plus»® in adult patients with moderate and severe atopic dermatitis. Methods. We examined 32 adult patients, who were treated with TGCS methylprednisolone aceponatis and «Bepanten Plus»®. The efficiency of therapy was estimated with index SCORAD, IGA and subjective patients assessment. For 15 of 32 patients swabs for bacterial isolation to estimate Staphylococcus aureus growth were taken from lesional skin before therapy and on the 14 th or 20 th days of treatment. Results. The аverage value of index SCORAD decreased after 15 days of therapy, Me 41,7 to Me 23,3 a point (p

Sign in / Sign up

Export Citation Format

Share Document